CAR T-cell therapies FDA approved for AYA B-ALL
| Trial . | No. of patients . | Median age (range), years . | CR/CRi (%) . | MRD-negativeCR in responders (%) . | Median RFS (mo) . | Median OS (mo) . | Unique toxicity . |
|---|---|---|---|---|---|---|---|
| Tisa-cel | |||||||
| ELIANA26 | 75 | 11 (3-23) | 81 | 100 | EFS at 12 months = 50% | 19.1 | CRS (any): 77% Gr. ≥3: 35% ICANS (any): 40% Grade ≥3: 13% |
| Brexu-cel | |||||||
| ZUMA-3, phase 1/228 | 78 | 42.5 (18-84) | 73 | 97 | 11.7 | 25.4 | CRS (any): 93% Gr. ≥3: 31% ICANS (any): 78% Gr. ≥3: 38% |
| Trial . | No. of patients . | Median age (range), years . | CR/CRi (%) . | MRD-negativeCR in responders (%) . | Median RFS (mo) . | Median OS (mo) . | Unique toxicity . |
|---|---|---|---|---|---|---|---|
| Tisa-cel | |||||||
| ELIANA26 | 75 | 11 (3-23) | 81 | 100 | EFS at 12 months = 50% | 19.1 | CRS (any): 77% Gr. ≥3: 35% ICANS (any): 40% Grade ≥3: 13% |
| Brexu-cel | |||||||
| ZUMA-3, phase 1/228 | 78 | 42.5 (18-84) | 73 | 97 | 11.7 | 25.4 | CRS (any): 93% Gr. ≥3: 31% ICANS (any): 78% Gr. ≥3: 38% |
CRi, complete remission with incomplete count recovery; CRS, cytokine release syndrome; Gr, grade, ICANS, immune effector cell-associated neurotoxicity syndrome.